Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

Mucosal Melanoma of the Head and Neck Clinical Trial

Official title:
Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

Status Recruiting

Clinical Trial Summary

This is an open-label, single center, one cohort, non-randomized, phase I/II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Melanoma
Mucosal Melanoma of the Head and Neck

Clinical Trial Details

NCT number	NCT04318717
Study type	Interventional
Source	Washington University School of Medicine
Contact	George Ansstas, M.D.
Phone	314-362-5677
Email	gansstas@wustl.edu
Status	Recruiting
Phase	Phase 2
Start date	May 29, 2020
Completion date	July 31, 2030

View Details

See also
	Status	Clinical Trial	Phase
	Withdrawn	`NCT03220009` - Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	Phase 2
	Recruiting	`NCT05111574` - Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery	Phase 2